Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 13, 2019 16:15 ET | Source: Zafgen, Inc.

Zafgen to Present at the JMP Securities Life Sciences Conference

BOSTON, June 13, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
June 10, 2019 07:00 ET | Source: Zafgen, Inc.

Zafgen Presented Full Results of Phase 2 Clinical Trial for ZGN-1061 at the American Diabetes Association's 79th Scientific Sessions

Delivered comprehensive oral presentation on both cohorts of the clinical trial, including previously announced results for second cohort evaluating doses up to 1.8 mg Company also presented data...
May 30, 2019 07:00 ET | Source: Zafgen, Inc.

Zafgen Announces Regulatory Update on ZGN-1061

Received FDA Type A meeting minutes related to previously announced clinical hold FDA acknowledged newly developed in vitro assays of human plasma coagulation and tissue factor expression...
May 09, 2019 16:15 ET | Source: Zafgen, Inc.

Zafgen Reports First Quarter 2019 Operating and Financial Results

Recently announced positive results for second cohort of Phase 2 clinical trial of ZGN-1061 Company is currently in the formal regulatory process related to the clinical hold for...
May 02, 2019 16:30 ET | Source: Zafgen, Inc.

Zafgen to Announce First Quarter 2019 Financial Results

BOSTON, May 02, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
April 04, 2019 16:30 ET | Source: Zafgen, Inc.

Zafgen, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, April 04, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN) (the “Company”) a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to...
March 13, 2019 17:00 ET | Source: Zafgen, Inc.

Zafgen to Present at the 31st Annual ROTH Conference

BOSTON, March 13, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
March 11, 2019 16:05 ET | Source: Zafgen, Inc.

Zafgen Reports Fourth Quarter and Full Year 2018 Operating and Financial Results and Provides Key Program and Business Updates

Recently announced positive results for second cohort of Phase 2 clinical trial of ZGN-1061 Updates on progress preparing for FDA Type A meeting for ZGN-1061 Suspends IND filing plans for ZGN-1258...
March 07, 2019 08:00 ET | Source: Zafgen, Inc.

Zafgen to Present at the Cowen and Company 39th Annual Health Care Conference

BOSTON, March 07, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
March 06, 2019 18:00 ET | Source: Zafgen, Inc.

Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2018 Financial Results

BOSTON, March 06, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...